scout
|Videos|June 24, 2015

Afatinib Versus Erlotinib in Advanced SCC of the Lung

Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME